The diagnostic tactics of doctor of general practices regarding patient with carbohydrate metabolism disoders

Prof. L.V. Zhuravlyova, N.V. Sokolnikova, D.I. Pylоv. Kharkiv National Medical University.

The purpose of the article was to examine the basic mechanisms of the pathogenesis of diabetes mellitus type 1 and 2, the most important clinical features and diagnostic criteria for disorders of carbohydrate metabolism. Results differential signs of diabetes type 1 and 2, as well as basic diagnostic and performance monitoring of glycemic profile. In addition to carbohydrate metabolism disturbances, described frequent metabolic disorders satellites diabetes: hypertension, dyslipidemia, weight gain. The article can be useful not only general practitioners, family medicine, but doctors another clinical specialties too.

Key Words: diabetes mellitus, diagnostic criteria, hyperglycemia, insulin resistance, dyslipidemia.

Zhuravlyova LV, Sokolnikova NV, Pylov DI. [The diagnostic tactics of doctor of general practices regarding patient with carbohydrate metabolism disoders]. Shidnoevr. z. vnutr. simejnoi med. 2016;2:98-104. Russian.


1. Abbasi A, Peelen LM, Corpeleijn E, van der Schouw YT, Stolk RP, Spijkerman AM, van der A DL, Moons KG, Navis G, Bakker SJ, Beulens JW. Prediction models for risk of developing type 2 diabetes: systematic literature search and independent external validation study. BMJ. 2012 Sep 18;345:e5900. doi: 10.1136/bmj.e5900. PubMed PMID: 22990994; PubMed Central PMCID: PMC3445426.
2. Bevier W, Zisser H, Jovanovic L, Finan D, Palerm C, Seborg D, Doyle F. Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone. J. Diabet Sci Technol. 2008;2(4):578—583.
3. Chetty V, Almulla A, Odueyungbo A, Thabane L. The effect of continuous subcutaneous glucose monitoring versus intermittent whole blood finger-stick glucose monitoring on hemoglobin A1c levels in Type I diabetic patients: a systematic review. Diabet Res Clin Pract. 2008;8(1):79—87.
4. Codario RA. Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome. NY.: Humana Press; 2011. 384 p.
5. Cooke D, Hurel S, Casbard A, Steed L, Walker S, Meredith S, Nunn A, Manca A, Sculpher M, Barnard M, Kerr D, Weaver J, Ahlquist J, Newman S. Randomized controlled trial to assess the impact of continuous glucose monitoring on HbA(1c) in insulin-treated diabetes (MITRE Study). Diabet Med. 2009;26(5):540—547.
6. Daenen S, Sola-Gazagnes A, M’Bemba J, Dorange-Breillard C, Defer F, Elgrably F, Larger E, Slama G. Peak-time determination of post-meal glucose excursions in insulintreated diabetic patients. Diabet Metabol. 2010;36(2):165—169.
7. Executive summary: Standards of medical care in diabetes: 2013. Diabetes Care. 2013;36(1):4—10.
8. Ferreiro L, Angiolillo DJ. Diabetes and antiplatelet therapy in acute coronary syndrome. Circulation. 2011;123:798—813.
9. G. de Simone, Devereux RB, Chinali M, et al. Diabetes and incident heart failure in hypertensive and normotensive participants of the Strong Heart Study. J. Hypertens. 2010;28(2):353-360.
10. Gerstein HC, Miller ME, Genuth S. et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 2011;364:818—828.
11. Gill RS, Sharmab AM, Gill SS, et al. The impact of obesity on diabetes mellitus and the role of bariatric surgery. Maturitas. 2011;69:137—140.
12. Griffin S, Borch-Johnsen K, Davies MJ, et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. J. Lancet. 2011;378:156—167.
13. Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of hemoglobin A (1c). J. Intern Med. 2011;271:227—236.
14. Hemmingsen B, Lund SS, Gluud C et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ 2011:343.d6898. doi: 10.1136/bmj.d6898.
15. IDF: Non-Communicable Diseases: time to pay attention to the silent killer. IDF 2010. Electronic resource link
16. Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2012;55:1577—1596.
17. Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil. 2011;18:393—398.
18. Oh K, Hu FB, Manson JE, et al. Abstract Dietary Fat Intake and Risk of Coronary Heart Disease in Women: 20 Years of Follow up of the Nurses’ Health Study. Am. J. Epidemiol. 2008;161(7):672—679.
19. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart. 2012;33:1635—1701.
20. Sarwar N, Gao P, Seshasai SR. Emerging rick factors collaboration. Diabetes mellitus, fasting blood glucose concentration, and rick of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-22.
21. Seshasai SR, Kaptoge S, Thompson A. et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N. Engl. J. Med. 2011;364:829—841.
22. Toouli J, Fried M, Khan AG, et al. Obesity. World Gastroenterology Organisation Global Guideline. WGO Global Guideline 2009. Electronic resource
23. Turnbull FM, Abraira C, Anderson RJ, et al Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52:2288—2298.
24. Wing RR, Bolin P, Brancati FL. et al. Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in type 2 diabetes. N. Engl. J. Med. 2013;369(2):145—154.
25. Wing RR. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010;170:1566—1575.
26. Zannad F, Stough WG, Pocock SJ. et al. Diabetes clinical trials: helped or hindered by the current shift in regulatory requirements?. Eur. Heart J. 2012;33:1049—1057.
27. Ambrosova TM. Markery kardiometabolichnogo ryzyku u hvoryh na arterial’nu gipertenziju z suputnim ozhyrinnjam i cukrovym diabetom 2 typu. Pytannja eksperymental’noi’ ta klinichnoi’ medycyny. Zbirnyk statej. 2010;10(1):11-17. Ukrainian.
28. Atlas diabeta. 6-e izd. [Internet]. International Diabetes Federation IDF; 2013. 161 p. Russian. Rezhim dostupa:
29. Barna ON. [Is Glycated Hemoglobin a Reliable and Accurate test for Diabetes Management?] Liky Ukrai’ny. 2014;2(178):17-21. Russian.
30. Abramova NA, Aleksandrov AA, Andreeva EN. Endokrinologiia. Natsional’noe rukovodstvo. Kratkoe izd. Dedov II, Mel’nichenko GA, editors. Moscow: Geotar-Media; 2013. 755 p. Russian.
31. Zhuravleva LV, Sokol’nikova NV. Sovremennye predstavleniia o sakharnom diabete: chto dolzhen znat’ kazhdyi vrach. Neiron-reviu. 2011;3:22—32. Russian.
32. Klasyfikacii’ kardiomiopatij ta miokardytiv. Materialy IX Nacional’nogo kongresu kardiologiv Ukrai’ny [Internet]. Kyi’v; 2008. Available from:; Ukrainian.
33. Kovalenko VN, Svishchenko EP. Arterial’naia gipertenziia u osobykh kategorii bol’nykh. Kiev: Morion; 2009. 374 p. Russian.
34. Kravchun NA, Karachentsev IuI, Goncharova OA, Kazakov AV, Gorshunskaia MIu. Dislipidemii pri endokrinnykh zabolevaniiakh. Khar’kov: Prapor; 2008. 224 p. Russian.
35. Mitchenko OI, Lutai MI. Dyslipidemii’: diagnostyka, profilaktyka ta likuvannja. Metodychni rekomendacii’ Asociacii’ kardiologiv ukrai’ny. Kyiv; 2011. 48 p. Ukrainian.
36. Unifikovanyi klinichnii protokol pervinnoi, ekstrenoi, vtorinnoi (specializovanoi) ta tretinnoi (visokospecializovanoi) medychnoi dopomogy cukrovyj diabet 1 typu u molodyh ljudej ta doroslyh: Nakaz Ministerstva oxoroni zdorovja Ukraini, 2014, No. 1021 (Dec. 29, 2014). Ukrainian.
37. Rekomendacii po diabetu, prediabetu i serdechnososudistim zabolevaniam. EASD ESC. Rossiskij kardiologicheskij zhurnal. 2014;3(107):7-61. Russian.
38. Rekomendacii’ Jevropejs’kogo tovarystva kardiologiv shhodo vedennja ta likuvannja pacijentiv z sercevo-sudynnymy zahvorjuvannjamy. Vyd. do II Nacional’nogo kongresu likariv vnutrishn’oi’ medycyny; 2008 Oct 16-18; Kyiv, Ukraine; 2008. 134 p. Ukrainian.
39. Tron’ko MD. Dovidnyk likarja-endokrynologa. Kyiv: Doktor-media; 2010. 209 p. Ukrainian.
40. Khvorostinka VN, Lesovoi VN, Moiseenko TA. Klinicheskaia endokrinologiia. Khvorostinka VN, editor. Kharkiv: Fakt; 2008. 541 p. Russian.